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Abstract
Background: Though 293T cells are widely used for expression of proteins from transfected plasmid vectors, the molecular
basis for the high-level expression is yet to be understood. We recently identified the prostate carcinoma cell line PC3 to be
as efficient as 293T in protein expression. This study was undertaken to decipher the molecular basis of high-level
expression in these two cell lines.
Methodology/Principal Findings: In a survey of different cell lines for efficient expression of platelet-derived growth factor-
B (PDGF-B), b-galactosidase (b-gal) and green fluorescent protein (GFP) from plasmid vectors, PC3 was found to express at
5–50-fold higher levels compared to the bone metastatic prostate carcinoma cell line PC3BM and many other cell lines.
Further, the efficiency of transfection and level of expression of the reporters in PC3 were comparable to that in 293T.
Comparative analyses revealed that the high level expression of the reporters in the two cell lines was due to increased
translational efficiency. While phosphatidic acid (PA)-mediated activation of mTOR, as revealed by drastic reduction in
reporter expression by n-butanol, primarily contributed to the high level expression in PC3, multiple pathways involving PA,
PI3K/Akt and ERK1/2 appear to contribute to the abundant reporter expression in 293T. Thus the extent of translational up-
regulation attained through the concerted activation of mTOR by multiple pathways in 293T could be achieved through its
activation primarily by the PA pathway in PC3.
Conclusions/Significance: Our studies reveal that the high-level expression of proteins from plasmid vectors is effected by
translational up-regulation through mTOR activation via different signaling pathways in the two cell lines and that PC3 is as
efficient as 293T for recombinant protein expression. Further, PC3 offers an advantage in that the level of expression of the
protein can be regulated by simple addition of n-butanol to the culture medium.
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Introduction
Gene expression in mammalian cells can be regulated at a single
or multiple levels involving chromatin structure, transcription,
post-transcription and translation leading to different genes being
expressed at widely varying levels in a cell type-specific manner or
in the same cell. Functional expression of a gene can further be
regulated by a multitude of post-translational mechanisms.
Currently, a very limited number of mammalian cell lines
amenable for efficient transfection and expression of proteins is
available. In contrast to lower eukaryotes or prokaryotes,
mammalian cells provide biologically active proteins with relevant
post-translational modifications. Unlike the tedious process
involving transfection, selection, isolation and characterization of
cell clones for expression by stable transfection of plasmid vectors,
expression by transient transfection provides a rapid means for
obtaining high concentrations of recombinant proteins. The
human embryonic kidney-derived HEK293 cells [1] exhibit very
high transfection efficiency and express the recombinant proteins
at high levels [2,3]. These cells were further modified by stable
expression of the SV40 large T antigen generating the HEK293T
(293T) cell line [4] which allows high level expression of proteins
through episomal amplification of plasmids that contain SV40
origin of replication. The COS cells generated by immortalization
of the African Green Monkey kidney cell line CV1 with
replication-defective SV40 genome producing the large-T antigen
have also been widely used for expression of recombinant proteins
[5]. However, the versatility of these systems is limited by the use
of vectors containing the relevant viral promoter and origin of
replication. Chinese Hamster Ovary (CHO) cells are also widely
used for stable expression of proteins, but are inefficient in protein
expression by transient transfection [6]. The finding of the human
cytomegalovirus major immediate early promoter as a powerful
and versatile enhancer-promoter unit for expression vectors in a
broad range of mammalian cells has obviated the need for specific
viral promoter-replication origin-based vectors which have limited
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14408ability to drive expression in many cell lines [7]. Though 293T
cells efficiently express genes from CMV promoter-driven vectors,
there is a need to identify other cells that exhibit broader
expression properties to express proteins that may not be
expressed in 293T cells.
In a search for cell lines for high level expression of platelet-
derived growth factor B (PDGF-B) from a transfected vector, the
human prostate carcinoma cell line PC3 was found to be
remarkably superior to many normal and tumour cell lines that
were tested and the expression levels were on par with those in
293T. Since little is known on the mechanism/s underlying the high
level expression from transfected vectors in 293T, it is of interest to
carry out comparative analysis of the molecular mechanisms/
signaling pathways that contribute to the high level expression
phenotype in these two celllines. Analysis of the mRNAand protein
levels of the reporters in PC3, PC3BM, HeLa, MA104 and 293T
revealed that the high-level expression of the reporters in PC3 is
primarily due to enhanced translation. Since the mammalian target
of rapamycin (mTOR) is the central controller of translation in
mammaliancells,tounderstand themolecularbasisfortranslational
up-regulation in PC3, we first examined the status of activation of
mTOR, its targets and other key translation regulators, and
signalingpathways inPC3,and PC3BM and HeLa. Similar analysis
between PC3 and 293T was also carried out to understand if the
translational up-regulation in the two cell lines is effected through
similar or dissimilar mechanisms. Our results reveal that while the
high-level expression of the reporters in PC3 is mediated by
activation of mTOR primarily through phosphatidic acid (PA)
pathway, multiple mechanisms appear to potentiate the concerted
up-regulation of translation in 293T.
Results
High level expression of recombinant proteins from
transfected expression vectors in PC3 and 293T cells
PDGF-B gene expression in vivo is normally restricted to
vascular endothelial cells [8], placental cytotrophoblasts [9,10]
and activated macrophages and monocytes [11,12], but its
expression is frequently deregulated in a variety of tumor cell
lines [13]. During investigations on the role of the long 39UTR of
PDGF-B mRNA in cell type-specific expression or deregulation of
its expression in tumor cells, PC3 was observed to express the
PDGF-B protein from the transfected pCMV-PDGF-B vector at
5–50-fold higher level compared to all other cell lines that were
used. It is to be noted that endogenous expression of PDGF-B
mRNA or protein in PC3 is undetectable as in normal embryonic
fibroblasts M413 and M426 (unpublished data).
To investigate if the high-level expression of PDGF-B from
transfected vector in PC3 is due to enhanced transcriptional, post-
transcriptional or translational events, comparative analysis of
RNA and protein levels of PDGF-B, b-gal and GFP from
transfected vectors in PC3, PC3BM, HeLa, 293T and MA104
cells was carried out. As shown in figure 1A, the level of PDGF-B
mRNA derived from pCMV-PDGF-B, as determined by RNase
protection assay using 1.0 mg of RNA from PC3 and 293T and
2.5 mg from other cells, was higher in PC3 than in HeLa and
PC3BM, but was slightly less than that in 293T. The levels of b-gal
and GFP mRNAs in PC3, PC3BM and HeLa were similar but
slightly higher in 293T and MA104 cells as estimated by semi-
quantitative RT-PCR (Figure 1B). However, the level of PDGF-B
protein as examined by radioimmunoprecipitation was very high
in PC3 and 293T in comparison to HeLa and PC3BM (Figure 1C).
Detection by western blotting of b-gal and GFP also revealed high
level expression of the reporters in PC3 and 293T in comparison
to other cell lines (Figure 1D), and their levels were similar in both
PC3 and 293T (Figure 1C and 1D). These results were further
confirmed by ELISA for b-gal (Figure 1E) and fluorescence
microscopy for GFP (Figure 1F). Analysis of GFP fluorescence
revealed that transfection efficiency in all the cells was similar.
While the intensity of fluorescence is very high in PC3 and 293T,
it was very weak in HeLa and PC3BM. The fold difference in GFP
and b-gal mRNA levels in PC3 with respect to PC3BM and HeLa
is approximately 1, though MA104 and 293T cells showed higher
mRNA levels than PC3 (Figure 1B and 1G). But the levels of both
reporter proteins were 5 to 10 fold higher in PC3 and 293T than
in the other cell lines (Figure 1D and 1G). Thus the fold
translational efficiency of the reporter mRNAs in PC3 and 293T
was around 5 to 10 higher when compared to PC3BM and HeLa
(Figure 1C, 1D, 1F and 1G). However, both RNA (2–3 fold) and
protein (20–50 fold) levels of PDGF-B were higher in PC3 and
293T when compared to those in HeLa and PC3BM suggesting
that the translational efficiency of PDGF-B mRNA in these cell
lines is .10-fold than in other cells.
Analysis of mTOR and its targets reveals
hyperphosphorylation and inactivation of translational
inhibitory factors in PC3
mTOR, a serine-threonine kinase, is the central controller of
translation in mammalian cells [14–16]. mTOR exists in two
structurally and functionally distinct multi-protein complexes
called mTORC1 and mTORC2 [17–19]. Two upstream elements
that regulate mTOR-signaling pathway include the Ras homolog
enriched in brain (Rheb), a small GTP-binding protein, and the
heterodimeric tuberous sclerosis complex 1 and 2 (TSC1/TSC2)
[17–23]. TSC2, a GTPase activating protein (GAP) for Rheb,
functions as a negative regulator of mTOR and facilitates the
formation of the inactive GDP bound form of Rheb from the
active GTP-bound form which activates mTOR kinase activity
[22,23]. Phosphorylation of TSC2-TSC1 by several signaling
cascades leads to its inactivation, leading to mTORC1 activation
[24–29]. Activated mTORC1 phosphorylates its two best-known
downstream effectors, the 4E-binding proteins (4EBPs) and the
ribosomal p70 S6 kinase (S6K1) [30–33]. Phosphorylation of these
two translational regulators is frequently used as an in vivo readout
for mTOR activation. 4EBP1 binds to the translation initiation
factor eIF4E and prevents the formation of the eIF4F complex at
the cap structure. Phosphorylated 4EBP1 fails to bind 4E, leading
to recruitment of ribosomes to the mRNA and translational
activation [34–36]. On the other hand, activated p70S6K1
phosphorylates the ribosomal protein S6 and eukaryotic elonga-
tion factor 2 kinase (eEF2K) leading to increased translational
efficiency. Eukaryotic elongation factor 2 (eEF2) binds GTP and
mediates the translocation step of translation elongation. Phos-
phorylation of eEF2 at T56 by eEF2K, within the GTP-binding
domain, interferes with its ability to bind the ribosome [37–40].
Further, phosphorylation of eEF2K at S366 by activated S6K1
inhibits its kinase activity, leading to efficient translation [41,42].
While the effects of mTORC1 are rapamycin sensitive, those of
mTORC2 are rapamycin-insensitive which primarily regulates
actin cytoskeletal polarization and reorganization [43,44].
To understand the mechanism of 5–10-fold higher translational
efficiency of the reporters in PC3 in comparison to PC3BM and
HeLa, the status of mTOR, its regulators and the target
translation factors in these three cell lines was examined. As
shown in figure 2A, while the levels of mTOR and TSC2 were
similar in the three cell lines, that of the phosphorylated TSC2
(S1254 phosphorylated by p38-activated kinase MK2 (MAP-
KAPK-2) [29] was less in PC3 than in the other cells. The activity
High Protein Expression in PC3
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in part by 4EBPs, [30–36], and by phosphorylation by Mnk1
[45,46]. As shown in figure 2B, though the levels of phosphor-
ylated forms of eIF4E were similar in PC3 and PC3BM but were
relatively less in HeLa, 4EBP1 was hyperphosphorylated at all the
four residues T37/46, T70 and S65 in PC3 than in the other cell
lines, which is necessary to inhibit its interaction with eIF4E
(Figure 2C). Further, the ribosomal protein S6 was hyper-
phosphorylated at S240 and S235 in PC3 in comparison to
PC3BM and HeLa. Though the level of the elongation factor
eEF2 was similar in PC3 and PC3BM but higher than in HeLa
(Figure 2E), the phosphorylated forms of the protein were not
detectable in any of the cell lines using the available antibody (data
not shown). However, eEF2K was significantly highly phosphor-
ylated in PC3 than in the other two cell lines (Figure 2E).
Analysis of the signaling pathways that regulate
translation
PI3K-PKB/Akt, ERK MAPK pathways as well as p38-
activated kinase MK2 function as the upstream positive regulators
of mTORC1 through phosphorylation and inactivation of TSC2-
TSC1 [24,27,29]. PI3K, activated by many growth signals,
phosphorylates phosphatidylinositol-4, 5-bisphosphate (PIP2) at
the 3-position to generate PIP3. PDK1 and PKB/Akt bind to PIP3
and are recruited to the membrane [47,48] resulting in the
phosphorylation of Akt by PDK1 and activation of Akt which
leads to phosphorylation of both S6K and 4EBP1
[14,15,17,19,24–26,36,47,48]. As shown in figure 2F, though
p70S6K is hyperphosphorylated at T421 (by ERK MAPK
pathways) in PC3, the level of phosphorylation at S371 and
T389 (by mTOR) is significantly lower than that in HeLa, and
HeLa and PC3BM, respectively (Figure 2F). While PDK1 is
hyperphosphorylated at S241 in the activation loop in PC3, no
significant differences in the levels of the p85 isoform of PI3K were
observed (Figure 2G). Although no significant differences in the
total Akt protein levels in the three cell lines were detected, the
level of phosphorylation of the protein at Y326 (phosphorylated by
Src), T308 (phosphorylated by PDK1) and S473 (phosphorylated
by mTORC2 or PDK2) in PC3 was lower than that in PC3BM
and HeLa (Figure 2H). Further, while PC3BM and HeLa
Figure 1. Analysis of RNA and protein levels derived from the transfected expression vectors of PDGF-B, GFP and b-Gal in PC3,
PC3BM, HeLa, 293T and MA104 cells. (A) PDGF-B mRNA levels were determined by RNase protection Assay. The 144 nt protected band
corresponds to PDGF-B and the 120 nt band represents that of b-Actin mRNA. (B) RT-PCR of b-Gal, GFP and b-Actin mRNA in pcDNA3-b-Gal and
pcDNA3-GFP transfected cells. (C) Radioimmunoprecipitation of PDGF-B protein expressed in pCMV-PDGF-B transfected cells using an N-terminal
antibody [69]. (D) Levels of b-Gal, GFP and b-Tubulin proteins in pcDNA3- b-Gal and -GFP transfected cells. 50 mg of transfected cell lysate was
analyzed for GFP and b-Gal levels by SDS-PAGE. (E) b-galactosidase assay using the b-Gal ELISA Kit from Roche Diagnostics. (F) Fluorescence
microscopy and bright field (BF) images of 293T, PC3BM, HeLa and PC3 cells transfected with pcDNA-GFP reporter gene construct. (G) Analysis of the
fold differences in expression of the reporter mRNA and protein levels between PC3 and HeLa, and PC3 and PC3BM.
doi:10.1371/journal.pone.0014408.g001
High Protein Expression in PC3
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ERK1/2 and p38 MAPK between themselves (Figure 2I) with the
level of each kinase in either Hela or PC3BM being similar to that
in PC3, the total protein levels of both the kinases are observed to
be very similar in all the three cell lines. These observations suggest
that PI3K-Akt and MAPK pathways are not major contributors of
mTOR activation in PC3.
The lipid second messenger, phosphatidic acid (PA) is another
important positive regulator of mTOR and protein synthesis
[49,50]. It mediates the mitogenic activation of mTOR signaling
to the downstream effectors through regulation of a large number of
protein kinases and phosphatases [49,50]. PA is generated from
phosphotidylcholine by phospholipase D (PLD) [50,51]. Two
mammalian isozymes of PLD, PLD1 and PLD2, have been
identified to date [50,51]. PLD1 has low basal activity, but can be
activated by PIP2, PIP3 and several regulators including PKCs,
small GTP binding proteins like RhoA, Rac1, ARF1, RalA, and
Cdc42 and phosphatases [51–57]. PA-dependent translation
activation occurs through the lipid messenger generated by PLD1
directly on mTOR (49–52, 55–58). mTOR can also be activated by
diacylglycerol kinase-produced PA [58]. Though the mechanism of
mitogen-dependent PLD2 activation is not fully understood, recent
studies indicate PLD2-derived PA binds to and activates p70S6K1
in a rapamycin-insensitive and mTOR-independent manner [59].
PKCs regulate the activity of PLD either through direct interaction
at the N-terminus or by phosphorylation [52–57]. While PKC and
Figure 2. Western blot analysis of key target proteins of mTOR pathway. Analysis of total protein and/or phosphorylated forms of (A) mTOR
and TSC2, (B) eIF4E, (C) 4EBP1, (D) S6, (E) eEF2 and eEF2K (F) p70S6K, (G) PI3K and PDK1, (H) Akt and (I) ERK1/2, p38 MAPK and PKC. 50 mg of cell
lysate was used for analysis of mTOR, TSC2, PI3K, PDK1, Akt, eEF2, 4EBP1 and S6 and 100 mg was used for detection of phosphorylated forms and
other proteins.
doi:10.1371/journal.pone.0014408.g002
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to control the folding and stability of Akt and conventional PKCs
through phosphorylation of the turn motif (TM) and hydrophobic
motif (HM) [19,61,62].
Analysis of the phosphorylation status of PKCs using the pPKC
(pan) (bII S660) antibody which recognizes PKC a, bI, bII, d, e, g
and h phosphorylated at the carboxy-terminal residue homologous
to S660 of PKC bII revealed that PKCs are considerably highly
phosphorylated in PC3 than in PC3BM and HeLa (Figure 2I).
Comparative analysis of the mTOR signaling Pathways in
PC3 and 293T cells
Since PC3 and 293T expressed the reporter RNA and protein at
comparable levels (Figure 1), we sought to examine if the observed
hyper-translationin these two cell lines is due to the activation of the
same or different signaling pathways. Comparative analysis of the
mTOR pathway target proteins, revealed that 4EBP1 is the only
protein that showed comparable levels of hyperphosphorylation at
T37/46 in both the cells lines (Figure 3A). While the levels of
p70S6K-T389, mTOR, pmTOR-S2448, TSC2, pTSC2-S1254,
pPDK1-S241, Akt, pAkt-S473 and pERK1/2 were considerably
high in 293T than in PC3, by contrast, the phosphorylated forms of
S6 and eEF2K (S366) were significantly higher in PC3 in
comparison to 293T (Figure 3A, B and C). As revealed by the
high levels of the phosphorylated forms of PDK1, Akt and ERK1/2
in 293T (Figure 3C), the two mTOR-activating signaling pathways,
PI3K/Akt and Raf/MEK/ERK MAPK, appeared to be highly
activated in 293T than in PC3. A remarkable observation was that
PKCs were hyperphosphorylated in PC3 than in 293T (Figure 3D)
suggesting that the two cell lines could significantly differ in the PA-
mediated mechanism of mTOR activation.
To assess the role of PA in the high-level expression phenotype
of PC3, we examined the effect of n-butanol, an inhibitor of PA
production, on reporter gene expression. PLD-mediated PA
production in vivo can be blocked by primary alcohols like ethanol
and n-butanol, which serve as a substrate in transphosphatidyla-
tion reaction by PLD to form phosphatidylethanol or phospha-
tidylbutanol [51–56]. Figure 4A and B illustrate that treatment of
cells with 0.4% n-butanol had a profound inhibitory effect on both
GFP and b-gal expression in PC3. However, though significant
reduction in GFP expression was observed, butanol had no effect
on b-gal expression in 293T cells (Figure 4B). n-butanol appears to
have also affected the level of phosphorylation of mTOR in both
cell lines (Figure 4C).
Since PI3K/Akt pathway appeared to have been highly
activated in 293T than in PC3, their role in high level reporter
expression in the two cell lines was evaluated using specific
pharmacological inhibitors. While no inhibitory effect of PI3K/
Akt inhibitors (Wotmannin, LY294002) on the expression of both
the reporters was observed in PC3 (Figure 4D and 4E), translation
of both reporters in 293T was inhibited by 50–75% with the
expression of GFP being more severely affected compared to that
of b-gal (Figure 4A and 4B). Though U0126 inhibited the
expression of both the reporters significantly in PC3, its effect in
293T was again reporter specific. While there was no effect on b-
gal expression in 293T, U0126 inhibited GFP expression by about
50% of that expressed in untreated cells. Thus the MEK/ERK
pathway inhibitor U0126 appears to exhibit reporter-specific
effects in 293T cells.
Discussion
Comparative analysis of RNA and protein levels of the reporters
in PC3, PC3BM, HeLa, MA104 and 293T cell lines indicated that
the GFP and b-gal mRNAs are translated at 5–10 fold higher
efficiency in PC3 and 293T (Figure 1C, 1D and 1G). It may be
noted that though the CMV promoter appears to be relatively
more active in MA104 cells, b-gal and GFP mRNAs are poorly
translated than in PC3 and 293T. However, the PDGF-B mRNA
levels were 2–3-fold higher in PC3 and 293T than in PC3BM and
HeLa. Since the mRNA levels of GFP and b-gal transcribed from
the CMV promoter in PC3, PC3BM and HeLa were similar, it is
Figure 3. Comparative analysis of the translational regulatory
proteins and different signaling pathway proteins in PC3 and
293 T cells. (A) Analysis of mTOR target proteins 4EBP1, S6, eEF2K and
p70S6K. (B) mTOR and TSC2. (C) PI3K/Akt and ERK1/2. (D) PKC. 200 mg
of cell lysate was used for PKC analysis and 50 mg was used for analysis
of other proteins.
doi:10.1371/journal.pone.0014408.g003
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selectively stabilized in PC3 and 293T. This aspect needs to be
further investigated. Though the PDGF-B protein is expressed at
20–50-fold higher level in PC3 and 293T than in PC3BM and
HeLa, the translational machinery in PC3 and 293T appears to be
about 10–17-fold more efficient than in the other cells.
The fact that 4EBP1 is a direct target of mTOR and that 4EBP1 is
hyperphosphorylated at all the 4 sites suggests that mTOR is more
activated in PC3 in comparison to PC3BM and HeLa. Increased
phosphorylation of mTOR at S2448 correlates with enhanced
phosphorylation of S6K (T421) and 4EBP1 (Figure 2). Activation of
p70 S6K1 depends on its level of phosphorylation state at eight sites:
T229 (catalytic domain), S371, T389 and S404 (linker domain) and
S411, S418, T421, and S424 (autoinhibitory domain) [63,64]. T229
(phosphorylated by PDK1) plays a key role in modulating S6K1
activity. S6K1 activation may be achieved by sequential phosphor-
ylation of these sites by MAPK pathways and PI3K [63,64]. S6K1
activation up-regulates ribosome biosynthesis, and enhances cell
translational capacity through phosphorylation of the 40S ribosomal
protein S6 (rpS6) and upregulation of translation of mRNAs having
59-terminal oligopyrimidine tracts (59TOP), but in an mTOR-
dependent, rapamycin–sensitive manner [36,37,65]. However, the
low level phosphorylation of p70S6K at S371 and T389 in PC3 in
comparison to PC3BM and HeLa does not correlate with the
translation up-regulation in PC3 (Figure 2). It is possible that p70S6K
could also be directly activated by PLD2-generated PA in PC3 [59].
Though hyperphosphorylation of PDK1 was observed, the lower
levels of phosphorylation of Akt at 3 positions in PC3 than in
PC3BM and HeLa, and the significant differences in the levels of
the phosphorylated forms of both ERK and p38 MAPK kinases
between PC3BM and HeLa suggest that these pathways do not
significantly contribute to translational up-regulation in PC3.
However, the MEK-ERK pathway appears to contribute, to some
extent, to the high level expression of the reporters as seen by the
reduced expression of GFP and b-gal by U0126 (Figure 4D and E).
The finding that PKCs (conventional and novel) are highly
phosphorylated in PC3 than in PC3BM and HeLa (Figure 2I) and
that mTOR phosphorylation at S2448 was higher with the Akt and
phospho-Akt levels being either similar or lower than in PC3BM
and HeLa suggest that mTOR in PC3 is primarily activated by PA-
mediated mechanism. Further, the level of phosphoTSC2 (phos-
phorylated by PI3K-Aktand MAPK pathways) is significantly lower
in PC3 than in the other two cell lines. The lack of inhibition of
reporter expression by wortmannin and LY294002 (Figure 4)
further suggests that PI3K-Akt pathway does not contribute to the
translation up-regulation of reporters in PC3. Activation of PKCs
requires phosphorylation in the activation loop (T500) by PDK1
[66] and our results indicate that PDK1 is hyperphosphorylated in
PC3. Although PA can mimic mitogens in the activation of the
mTOR downstream signaling pathway, PI3K is not activated in PA
treated cells [49], but wortmannin blocks the action of PA
suggesting that basal PI3K activity is required for PA to activate
mTOR [38]. This suggests that basal PI3K activity, as seen by
PDK1 phosphorylation, is required for activation of PKCs in PC3.
Comparative analyses revealed that 293T and PC3 significantly
differed in the activation of components of different signaling
pathways. The only similarity that was observed between the two
cell lines was in the level of 4EBP1 phosphorylation at T37/46.
While the levels of phospho pKC (pan), S6 and eEF2K were
significantly higher in PC3 than in 293T cells, the protein levels
and/or the levels of the phosphorylated forms of p70S6K, mTOR,
TSC2, PDK1 and Akt were notably higher in 293T cells than in
PC3 (Figure 3). The higher levels of phospho TSC2 correlates with
the robust activation of both the PI3K/Akt and ERK MAPK
pathways in 293T than in PC3. The dramatic hyper-phosphor-
ylation of PKCs in PC3 than in 293T indicates that efficient
translation of reporters in PC3 is primarily mediated by PA-
mediated mechanism while that in 293T is mediated by the
concerted action of PI3K/Akt and MAPK pathways (Figure 5).
The significant inhibition of reporter expression by wortmannin
and LY294002 in 293T but not in PC3 in contrast to the severe
inhibitory effect of n-butanol in PC3 in comparison to 293T
Figure 4. Analysis of the differential effect of n-Butanol, U0126,
Wortmannin and LY294002 on reporter gene expression and
phosphorylation of mTOR in transfected PC3 and 293T cells.
Effect of n-butanol on expression of (A) GFP; (B) b-Gal, and (C) Inhibition
of phosphorylation of mTOR by n-butanol; Effect of U0126 (U0),
Wortmannin (Wort) and LY294002 (LY) on (D) b-Gal and (E)G F P
expression. Proteins were separated by 12–14% SDS-PAGE and detected
by immunoblotting using antibodies specific to GFP and b-Gal.
doi:10.1371/journal.pone.0014408.g004
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appears to influence the high level expression in 293T as seen by
the significant reduction in GFP but not b-gal expression by n-
butanol (Figure 4A and 4B). U0126 also exhibited differential
inhibitory effect on reporter expression in the two cell lines. While
U0126 partially inhibited the expression of both reporters in PC3,
it had no effect on b-gal expression in 293T. The reporter-specific
effects observed with U0126 and n-butanol in 293T could be due
to differences in the reporter mRNA and/or protein stability in the
presence of the inhibitors. Our results suggest that inhibition of a
single pathway could be partially compensated by other pathways
and as such no drastic effect on reporter expression is observed by
inhibition of any single pathway in 293T while PA-mediated
pathway of translational up-regulation appears to be very crucial
in PC3. In spite of the significant differences in the activation of
different factors/pathways, both cells appear to have attained
similar levels of enhanced translational capacity.
Our studies identify PC3 cell line to be as efficient as 293T in
transfection efficiency and recombinant protein expression
capacity. PC3 offers added advantage in that the level of protein
expression from the transfected vector can be elegantly regulated
by addition of different amounts of the inexpensive n-butanol to
the culture medium.
Materials and Methods
Enzymes, reagents and oligonucleotides
AMV reverse transcriptase, restriction endonucleases, Taq
DNA polymerase, T4 DNA ligase, protein molecular weight
markers and other reagents were purchased from either Promega
Biotech, Roche Applied Science, Invitrogen or Bio-Rad. The
reporter-specific oligonucleotide primers were purchased from
either Microsynth (Switzerland) or Sigma-Aldrich.
Cell lines
The cell lines PC3, PC3BM, HeLa, 293T and MA104 were
maintained in DMEM supplemented with 10% fetal bovine serum
(FBS) (Invitrogen).
Antibodies
Anti PDGF-B antibody was raised in the laboratory using MAP-
peptide corresponding to the N-terminal region of PDGF-B
[9,67]. This antibody recognizes the PDGF-B polypeptide having
an uncleaved N-terminus. Anti b-tubulin and GFP antibodies were
from BD Biosciences and b-gal antibody was from Promega,
respectively. All other antibodies were from Cell Signaling. The
secondary anti-rabbit HRPO or anti-mouse HRPO antibodies
were from GE Healthcare.
Reporter gene construction
The pCMV-PDGF-B construct contains the PDGF-B cDNA
region starting from nt 984–3373 that contains the open reading
frame and the complete 39 UTR followed by the 39 genomic
flanking sequence containing the 39 processing signals [9] placed
downstream of the cytomegalovirus (CMV) promoter. The Hind
III-Dra I fragment of the b-gal gene from the vector pCH110
(Pharmacia) was subcloned in pBS (pBluescript, Stratagene)
Figure 5. Schematic representation of activation of mTOR by common and distinct signaling pathways leading to translational up-
regulation in (A) PC3 and (B) 293T cell lines.
doi:10.1371/journal.pone.0014408.g005
High Protein Expression in PC3
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14408between the Hind III and EcoR V sites. The Hind III – BamH I
b-gal fragment was then cloned downstream of the CMV
promoter in pcDNA3.0 (Invitrogen) between the same sites to
generate pcDNA-b-gal. The GFP open reading frame was PCR
amplified from pF25-Rev-GFP [68] using primers mentioned
below and subcloned in pBS between the EcoR V and Not I sites
and was then inserted in pcDNA3.0 between the same sites
generating pcDNA-GFP. The sequences of the primers used for
GFP amplification are: 59 primer 59ATCGATATCCCGGGAT-
GAGCAAAGCAGAAGAACTC-39 and 39 primer: 59- AGTGC-
GGCCGCTCAGTTGTACAGTTCATCC -39.
Transfection and extraction of total RNA and protein
PC3, PC3BM, 293T, HeLa and MA104 cells grown to 50%
confluency were transfected with three micrograms (mg) of vector
DNA complexed with 6 ml of FuGENE 6 transfection reagent
(Roche Applied Science) in 100 mm dish according to supplier’s
protocol. After 40–48 hours of transfection, total RNA or protein
was extracted. Total RNA was extracted from the transfected cell
lines using RNeasy minikit (Qiagen). For protein extraction, the
cells were washed in tris-buffered saline (TBS) and lysed in 400 ml
of ice-cold 16 RIPA buffer (50 mM Tris, 150 mM NaCl, 1%
NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecylsulphate
(SDS) and 1 mM EDTA with protease inhibitor cocktail
(Roche Applied Science). The lysates were centrifuged and
protein concentration was determined by Bio-Rad Protein Assay
reagent.
Analysis of PDGF-B mRNA and protein expression
Total RNA, from the pCMV-PDGF-B-transfected PC3 (1.0 mg)
and HeLa (2.5 mg), PC3BM (2.5 mg) and 293T (1.0 mg) cells, was
analyzed by RNase protection assay using the RPA II kit from
Ambion. The probe used for PDGF-B is from Bgl II site to the 4/5
exon junction spanning the position 1407–1548 nt [9] which
yields a protected fragment of 141 nt in length. b-actin probe is
prepared by transcription from pTRI-b-actin plasmid from
Ambion using T7 RNA polymerase. This probe gives a protected
fragment of size 121 nt.
For analysis of protein expression, 40 hours after transfection,
cells were incubated for 30 min in medium lacking Met and Cys,
followed by incubation for 4 hours in medium supplemented with
50 mCi each of [
35S]-labelled Met and Cys. Cells were then lysed
in 400 ml of RIPA buffer. About 800 mg of the labeled lysate was
incubated with primary antibody (anti-N-terminal Ab against
PDGF-B) [67,69] for 1 hour, then 3–5 mg equivalent of Protein A
Sepharose (swollen in RIPA) was added, incubated by continuous
rotation at 4uC for 2 hours. The beads were washed thrice with
RIPA buffer, Laemmli buffer was added, boiled for 10 min at
95uC and the proteins were resolved by 14% SDS-PAGE. The gel
was fixed in 30:15% methanol-acetic acid solution for 30 min,
incubated in Enlightning Rapid Autoradiography Enhancer
(Perkin Elmer) for 30 min, dried and exposed to X-ray film
(Kodak XRP).
RNA and Protein analysis of GFP and b-gal
RT-PCR was done using 0.3 mg of total RNA from b-gal and
GFP-transfected cells using the Qiagen One step RT-PCR kit. b-
gal and GFP mRNAs were amplified for 35 cycles and b-actin for
25 cycles. The forward and reverse primers used for GFP are: 59-
GCAACATACGGAAAACTTACCCTGA-39and59-CACTTT-
GATTCCATTCTTTTGTTTGTC-39and those of b-gal are 59-
GAGCGAAAAATACATCGTCACCT-39 and 59-CAGGCAA-
AGCGCCATCGCCATTCA-39. For protein analysis, PC3,
PC3BM, HeLa, 293T and MA104 cells, grown in 100 mm cell
culture dishes, were washed thrice in ice cold TBS and lysates were
prepared in 600 mlo f1 6RIPA buffer. Protein concentration was
estimated using Bio-Rad Protein Assay reagent. Equal amounts of
protein (50 mg) from different cells were analyzed by SDS-PAGE
followed by western blot analysis using a chemiluminescence kit
(Immobilon
TM Western, Millipore).
b-Galactosidase Assay
The cell extracts from the pcDNA-b-gal transfected cells were
assayed for b-galactosidase activity using the b-gal ELISA kit from
Roche Diagnostics.
Fluorescence Microscopy
Cells transfected with pcDNA-GFP were examined using
fluorescence Leica DM IRB microscope and the images were
captured using Leica DC 300F digital camera, and were analyzed
with the Leica IM500 Image Manager software.
Analysis of translation factors in different cell lines
PC3, PC3BM, HeLa and 293T cells grown in 100 mm dishes
were washed thrice in ice cold TBS and lysates prepared in cold
16 RIPA buffer (600 ml) containing 10 mM sodium pyrophos-
phate and 1 mM sodium orthovanadate and protease inhibitor
cocktail. 50 mg of protein from different cell lines was used for
analysis by SDS-PAGE and immunoblotting.
Evaluation of the effect of n-butanol, Wortmannin,
LY294002 and U0126 on the expression of b-gal and GFP
reporters in PC3 and 293T cells
PC3 and 293T cells were grown to 50% confluency, media
containing the serum was removed and the cells were pretreated or
not treated with 0.4% n-butanol,Wortmanin(0.10 mM), LY294002
(30 mM) and U0126 (50 mM) (Cell Signaling) for 2 hours. The cells
were then transfected for 4 hours with 3 mg of either pcDNA-GFP
or pcDNA-b-gal DNA in fresh complete medium lacking the
inhibitor. Cells were then grown in complete medium containing or
lacking the compounds at indicated concentrations. b-gal and GFP
expression was analyzed 40–48 hours after transfection.
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